Clinical Trial Update: A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the interaction between LY317615 and warfarin to assess metabolic pathway effects; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma Malignant
• Solid Tumor

Drugs mentioned

• LY317615
• Warfarin (warfarin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Solid Tumor, Lymphoma, Malignant | Phase 1 | Status: COMPLETED | Results posted: 2020-07-01